Cidofovir → Hpmpc diea

HRID 560966

반응식

HRID 560966 반응식
[CH3:1][CH2:2][N:3]([CH:7]([CH3:9])[CH3:8])[CH:4]([CH3:6])[CH3:5].[CH:10]1[C:16]([NH2:17])=[N:15][C:13](=[O:14])[N:12]([CH2:18][C@H:19]([O:22][CH2:23][P:24]([OH:27])([OH:26])=[O:25])[CH2:20][OH:21])[CH:11]=1>CN(C=O)C>[CH:10]1[C:16]([NH2:17])=[N:15][C:13](=[O:14])[N:12]([CH2:18][C@H:19]([O:22][CH2:23][P:24]([OH:27])([OH:26])=[O:25])[CH2:20][OH:21])[CH:11]=1.[CH3:1][CH2:2][N:3]([CH:7]([CH3:9])[CH3:8])[CH:4]([CH3:6])[CH3:5]

참가 물질

4

반응물 2

HCID 60613CidofovirHCID 81531Diisopropylethylamine

생성물 1

HCID 131727369Hpmpc diea

시약·촉매·용매 1

HCID 6228Dimethylformamide용매

실험 절차

5 mL of DMF and 400 μL of DIEA was added to 200 mg (0.63 mmol) HPMPC to produce a HPMPC-DIEA salt. Solvent was removed under vacuo and HPMPC-DIEA salt was carefully dried. 1.5 times excess of desired dipeptide from the general procedure described above was added to the dry HPMPC-DIEA salt, as well as 7 mL dry DMF and 400 μL DIEA. The mixture was heated for 1 h at 40° C. before 660 mg (1.3 mmol) PyBOP was added. Reaction was monitored by 31P NMR, and additional portions of PyBOP were added until the reaction was completed. Solvent was removed under vacuo, and purified by silica gel column chromatography [Solvent system: (CH2Cl2), (CH2Cl2: acetone, 2:1), (CH2Cl2: acetone: MeOH, 20:10:3)].

출처 및 근거

ORD 기록
ord-c78d0168f3fd4f69b75d2d10a111ac83
출처 데이터셋
uspto-grants-2011_11
특허 번호
US08063209B2

연결된 노트

불러오는 중…